240 related articles for article (PubMed ID: 30753507)
1. Diagnostic performances of 68Ga-DOTATOC versus 18Fluorodeoxyglucose positron emission tomography in pulmonary carcinoid tumours and interrelationship with histological features.
Lococo F; Rapicetta C; Mengoli MC; Filice A; Paci M; Di Stefano T; Coruzzi C; Versari A
Interact Cardiovasc Thorac Surg; 2019 Jun; 28(6):957-960. PubMed ID: 30753507
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the role of [18F]FDG-PET/CT and [68Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids.
Jindal T; Kumar A; Venkitaraman B; Meena M; Kumar R; Malhotra A; Dutta R
Cancer Imaging; 2011 Jun; 11(1):70-5. PubMed ID: 21697027
[TBL] [Abstract][Full Text] [Related]
3. Role of (68)Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids.
Jindal T; Kumar A; Venkitaraman B; Dutta R; Kumar R
Korean J Intern Med; 2010 Dec; 25(4):386-91. PubMed ID: 21179276
[TBL] [Abstract][Full Text] [Related]
4. Multicenter comparison of 18F-FDG and 68Ga-DOTA-peptide PET/CT for pulmonary carcinoid.
Lococo F; Perotti G; Cardillo G; De Waure C; Filice A; Graziano P; Rossi G; Sgarbi G; Stefanelli A; Giordano A; Granone P; Rindi G; Versari A; Rufini V
Clin Nucl Med; 2015 Mar; 40(3):e183-9. PubMed ID: 25608152
[TBL] [Abstract][Full Text] [Related]
5. Role of 68Ga-DOTATOC PET/CT in initial evaluation of patients with suspected bronchopulmonary carcinoid.
Venkitaraman B; Karunanithi S; Kumar A; Khilnani GC; Kumar R
Eur J Nucl Med Mol Imaging; 2014 May; 41(5):856-64. PubMed ID: 24435773
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.
Kowalski J; Henze M; Schuhmacher J; Mäcke HR; Hofmann M; Haberkorn U
Mol Imaging Biol; 2003; 5(1):42-8. PubMed ID: 14499161
[TBL] [Abstract][Full Text] [Related]
7. 68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: A prospective study in Taiwan.
Chen SH; Chang YC; Hwang TL; Chen JS; Chou WC; Hsieh CH; Yeh TS; Hsu JT; Yeh CN; Tseng JH; Chen TC; Yen TC
J Formos Med Assoc; 2018 Jun; 117(6):480-487. PubMed ID: 28735662
[TBL] [Abstract][Full Text] [Related]
8. Dual-Tracer (68Ga-DOTATOC and 18F-FDG-)-PET/CT Scan and G1-G2 Nonfunctioning Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Evaluation of 124 Nonmetastatic Resected Cases.
Paiella S; Landoni L; Tebaldi S; Zuffante M; Salgarello M; Cingarlini S; D'Onofrio M; Parisi A; Deiro G; Manfrin E; Bianchi B; Montagnini G; Crinò SF; Bassi C; Salvia R
Neuroendocrinology; 2022; 112(2):143-152. PubMed ID: 33508821
[TBL] [Abstract][Full Text] [Related]
9. The utility of 18F-FDG and 68Ga-DOTA-Peptide PET/CT in the evaluation of primary pulmonary carcinoid: A systematic review and meta-analysis.
Jiang Y; Hou G; Cheng W
Medicine (Baltimore); 2019 Mar; 98(10):e14769. PubMed ID: 30855482
[TBL] [Abstract][Full Text] [Related]
10. Role of 68Ga-DOTATOC PET/CT in carcinoids.
Jindal T; Kumar A; Kumar R; Dutta R
Pathol Int; 2010 Feb; 60(2):143-4. PubMed ID: 20398201
[No Abstract] [Full Text] [Related]
11. The diagnostic and prognostic role of combined [
Albano D; Dondi F; Bauckneht M; Albertelli M; Durmo R; Filice A; Versari A; Morbelli S; Berruti A; Bertagna F
Eur Radiol; 2023 Jun; 33(6):4167-4177. PubMed ID: 36482218
[TBL] [Abstract][Full Text] [Related]
12. Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours.
Krüger S; Buck AK; Blumstein NM; Pauls S; Schelzig H; Kropf C; Schumann C; Mottaghy FM; Hombach V; Reske SN
J Intern Med; 2006 Dec; 260(6):545-50. PubMed ID: 17116005
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
Koukouraki S; Strauss LG; Georgoulias V; Eisenhut M; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1115-22. PubMed ID: 16763820
[TBL] [Abstract][Full Text] [Related]
14. 68Ga-DOTATOC and FDG PET Imaging of Preclinical Neuroblastoma Models.
Provost C; Prignon A; Cazes A; Combaret V; Delattre O; Janoueix-Lerosey I; Montravers F; Talbot JN
Anticancer Res; 2016 Sep; 36(9):4459-66. PubMed ID: 27630282
[TBL] [Abstract][Full Text] [Related]
15. [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer--initial experience.
Lapa C; Lückerath K; Rudelius M; Schmid JS; Schoene A; Schirbel A; Samnick S; Pelzer T; Buck AK; Kropf S; Wester HJ; Herrmann K
Oncotarget; 2016 Feb; 7(8):9288-95. PubMed ID: 26843617
[TBL] [Abstract][Full Text] [Related]
16. Dual tracer 68Ga-DOTATOC and 18F-FDG PET/computed tomography radiomics in pancreatic neuroendocrine neoplasms: an endearing tool for preoperative risk assessment.
Mapelli P; Partelli S; Salgarello M; Doraku J; Pasetto S; Rancoita PMV; Muffatti F; Bettinardi V; Presotto L; Andreasi V; Gianolli L; Picchio M; Falconi M
Nucl Med Commun; 2020 Sep; 41(9):896-905. PubMed ID: 32796478
[TBL] [Abstract][Full Text] [Related]
17. Outcome Analysis of First-line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of
Bongiovanni A; Recine F; Riva N; Foca F; Liverani C; Mercatali L; Nicolini S; Pieri F; Amadori D; Ibrahim T
Clin Lung Cancer; 2017 Jul; 18(4):415-420. PubMed ID: 27956089
[TBL] [Abstract][Full Text] [Related]
18. Intraindividual comparison of
Ouvrard E; Chevalier E; Addeo P; Sahakian N; Detour J; Goichot B; Bachellier P; Karcher G; Taïeb D; Imperiale A
Clin Endocrinol (Oxf); 2021 Jan; 94(1):66-73. PubMed ID: 32790887
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.
Gaertner FC; Beer AJ; Souvatzoglou M; Eiber M; Fürst S; Ziegler SI; Brohl F; Schwaiger M; Scheidhauer K
Invest Radiol; 2013 May; 48(5):263-72. PubMed ID: 23385399
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of
Nakamoto Y; Ishimori T; Shimizu Y; Sano K; Togashi K
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1524-1530. PubMed ID: 30847538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]